Stoke Therapeutics (NASDAQ:STOK) General Counsel Sells $300,529.08 in Stock

Key Points

• Stoke Therapeutics' General Counsel, Jonathan Allan, sold 14,922 shares for over $300,000, reducing his stake in the company by 45% to approximately 18,176 shares.
• The company's stock has a 12-month trading range between $5.35 and $20.45, and it recently traded at $19.77 with a market capitalization of $1.08 billion.
• Stoke Therapeutics reported a loss per share of $0.40 in its last earnings call, exceeding analyst expectations, but revenue was significantly under forecast at $13.82 million.

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) General Counsel Jonathan Allan sold 14,922 shares of the business's stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $20.14, for a total value of $300,529.08. Following the transaction, the general counsel owned 18,176 shares in the company, valued at approximately $366,064.64. This represents a 45.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Jonathan Allan also recently made the following trade(s):

• On Wednesday, September 3rd, Jonathan Allan sold 6,345 shares of Stoke Therapeutics stock. The shares were sold at an average price of $20.07, for a total value of $127,344.15.
• On Friday, August 29th, Jonathan Allan sold 850 shares of Stoke Therapeutics stock. The shares were sold at an average price of $20.00, for a total value of $17,000.00.
• On Wednesday, August 13th, Jonathan Allan sold 13,712 shares of Stoke Therapeutics stock. The shares were sold at an average price of $15.00, for a total transaction of $205,680.00.

Stoke Therapeutics Price Performance

NASDAQ STOK traded up $0.18 during trading hours on Wednesday, hitting $19.77. The company's stock had a trading volume of 1,307,730 shares, compared to its average volume of 810,410. Stoke Therapeutics, Inc. has a 12 month low of $5.35 and a 12 month high of $20.45. The company has a market cap of $1.08 billion, a P/E ratio of 23.26 and a beta of 1.14. The company's 50 day simple moving average is $14.42 and its two-hundred day simple moving average is $10.83.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last released its earnings results on Tuesday, August 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.17. The company had revenue of $13.82 million during the quarter, compared to analyst estimates of $31.51 million. Stoke Therapeutics had a net margin of 26.25% and a return on equity of 18.32%. As a group, research analysts predict that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have commented on the company. BTIG Research set a $28.00 price objective on Stoke Therapeutics and gave the company a "buy" rating in a research report on Monday, August 18th. Chardan Capital reaffirmed a "buy" rating and set a $24.00 target price on shares of Stoke Therapeutics in a research report on Wednesday, August 13th. Cantor Fitzgerald raised Stoke Therapeutics to a "strong-buy" rating in a research report on Wednesday, May 14th. Wedbush raised their price objective on Stoke Therapeutics from $16.00 to $22.00 and gave the stock an "outperform" rating in a research report on Wednesday, August 13th. Finally, HC Wainwright dropped their price objective on shares of Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating on the stock in a report on Wednesday, May 14th. Two investment analysts have rated the stock with a Strong Buy rating and seven have issued a Buy rating to the stock. According to data from MarketBeat.com, Stoke Therapeutics has an average rating of "Buy" and an average price target of $25.57.

Institutional Investors Weigh In On Stoke Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Toronto Dominion Bank acquired a new stake in Stoke Therapeutics during the 4th quarter worth approximately $35,001,000. Corient Private Wealth LLC purchased a new position in Stoke Therapeutics during the 2nd quarter worth $7,489,000. RTW Investments LP raised its holdings in shares of Stoke Therapeutics by 10.1% in the fourth quarter. RTW Investments LP now owns 5,123,525 shares of the company's stock valued at $56,512,000 after buying an additional 471,240 shares during the last quarter. Checkpoint Capital L.P. lifted its stake in shares of Stoke Therapeutics by 139.3% in the 1st quarter. Checkpoint Capital L.P. now owns 730,717 shares of the company's stock worth $4,859,000 after acquiring an additional 425,330 shares during the period. Finally, Erste Asset Management GmbH acquired a new stake in shares of Stoke Therapeutics in the 1st quarter valued at approximately $2,670,000.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.